Director Dealings / Market Share Sale and Purchase

RNS Number : 4911X

Oxford Biomedica PLC

10 August 2018

 

Director Dealings / Market Share Sale and Purchase

Oxford, UK - 10 August 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), a leading gene and cell therapy group, was informed that on 07 August 2018 John Dawson, Chief Executive Officer, exercised options over 20,000 ordinary shares of 50p each ("Ordinary Shares") in the Company.  The options were exercisable at a cost of 50p per share and Mr Dawson has sold 10,046 shares at 890.1p in order to fund the £89,420 cost of exercise. These options were granted in October 2008, under the Company's 2007 Long Term Incentive Plan, and which were due to expire. 

Following the exercise Mr Dawson holds 88,468 ordinary shares of 50p each ("Ordinary Shares") in the Company, 0.13% of the Company's issued share capital.

The issued share capital of the Company is 65,752,788 ordinary shares of 50 pence each.

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

Notification of Dealing Form

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	John Dawson
2.	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford BioMedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Exercise of options
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) £0.50 20,000
e)	Aggregated information -   Aggregate volume -   Price -   Aggregated total	20,000 £0.50 £10,000.00
f)	Date of the transaction	2018-08-07
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)

1.	Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")
a)	Name	John Dawson
2.	Reason for the notification
a)	Position/status	Chief Executive Officer
b)	Initial notification/ amendment	Initial Notification
3.	Details of the Issuer
a)	Name	Oxford BioMedica plc
b)	LEI code	213800S1GVQNXQ15K851
4.	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument Identification code	Ordinary Shares of 50 pence each ISIN: GB00BDFBVT43
b)	Nature of the transaction	Disposal
c)	Currency	GBP - British pound
d)	Price(s) and volumes(s)	Price(s) Volume(s) £8.901093 10,046
e)	Aggregated information -   Aggregate volume -   Price -   Aggregated total	10,046 £8.901 £89,420.38
f)	Date of the transaction	2018-08-07
g)	Place of the transaction	London Stock Exchange, Main Market (XLON)

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson,  Chief Executive Officer Stuart Paynter, Chief Financial Officer	Tel: [phone]
Financial and corporate communications enquiries: Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Olivia Manser/Laura Thornton	Tel: [phone]

Notes for editors

About Oxford BioMedica^®

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector^®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, Axovant, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

DSHPMMMTMBJBBAP